共 50 条
- [21] FEASIBILITY OF RADICAL PROSTATECTOMY FOLLOWING NEOADJUVANT IXABEPILONE FOR HIGH-RISK PROSTATE CANCER: A PHASE II CLINICAL TRIALJOURNAL OF UROLOGY, 2013, 189 (04): : E314 - E315Maddox, MichaelLayton, JodiTaber, AngelaMega, AnthonyRenzulli, Joseph, II
- [22] A Phase I Clinical Trial of Vaccination With KIF20A-derived Peptide in Combination With Gemcitabine For Patients With Advanced Pancreatic CancerJOURNAL OF IMMUNOTHERAPY, 2014, 37 (01) : 36 - 42Suzuki, NobuakiHazama, ShoichiUeno, TomioMatsui, HirotoShindo, YoshitaroIida, MichihisaYoshimura, KiyoshiYoshino, ShigefumiTakeda, KazuyoshiOka, Masaaki
- [23] Neoadjuvant treatment with camrelizumab in combination with doxorubicin and ifosfamide: A phase II clinical study of high-risk soft tissue sarcomaJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Tang, QinglianZhang, Xin-KeZhu, XiaojunZhang, YingchunWang, Jin
- [24] Quality of life in a multicenter phase II trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinomaJOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)Aybar, Pablo Emilio SerranoHerman, Joseph M.Zalupski, MarkKim, Edward Jae-HoonBen-Josef, EdgarBekaii-Saab, Tanios S.Wolfgang, Christopher LeeLaheru, Daniel A.Moore, Malcolm J.Dawson, Laura A.Ringash, JolieWei, Alice Chia-chi
- [25] Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (03) : 230 - +Macarulla, TeresaPazo-Cid, RobertoGuillen-Ponce, CarmenLopez, RafaelVera, RuthReboredo, MargaritaMunoz Martin, AndresRivera, FernandoDiaz Beveridge, RobertoLa Casta, AdelaidaMartin Valades, JoseMartinez-Galan, JoaquinaAles, ImmaculadaSastre, JavierPerea, SofiaHidalgo, Manuel
- [26] A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancerMedical Oncology, 2018, 35Kei SaitoHiroyuki IsayamaYoshihiro SakamotoYousuke NakaiKazunaga IshigakiMariko TanakaTakeyuki WatadaniJunichi AritaNaminatsu TakaharaSuguru MizunoHirofumi KogureHideaki IjichiKeisuke TateishiMinoru TadaKiyoshi HasegawaMasashi FukayamaNorihiro KokudoKazuhiko Koike
- [27] A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancerMEDICAL ONCOLOGY, 2018, 35 (07)Saito, KeiIsayama, HiroyukiSakamoto, YoshihiroNakai, YousukeIshigaki, KazunagaTanaka, MarikoWatadani, TakeyukiArita, JunichiTakahara, NaminatsuMizuno, SuguruKogure, HirofumiIjichi, HideakiTateishi, KeisukeTada, MinoruHasegawa, KiyoshiFukayama, MasashiKokudo, NorihiroKoike, Kazuhiko
- [28] In Vivo Inhibition of BCR Activation in High-Risk CLL Patients On Therapy with Bruton's Tyrosine Kinase Inhibitor Ibrutinib: Correlative Studies from an Ongoing Phase 2 Clinical TrialBLOOD, 2012, 120 (21)Hoellenriegel, JuliaO'Brien, SusanKeating, Michael J.Wierda, William G.Buggy, Joseph J.Burger, Jan A.
- [29] Phase I study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcomas.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Tseng, William W.Zhou, ShouhaoThall, Peter F.Lazar, Alexander J. F.Pollock, Raphael E.Lin, Patrick P.Cormier, Janice N.Feig, Barry W.Hunt, KellyBallo, Matthew T.Patel, ShreyaskumarPisters, Peter W. T.
- [30] Quality of Life in a Multi-enter Phase II Trial of Neoadjuvant Full Dose Gemcitabine, Oxaliplatin and Radiation in Patients with Resectable or Borderline Resectable Pancreatic AdenocarcinomaANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S32 - S32Serrano, P. E.Herman, J. M.Laheru, D. A.Wolfgang, C.Zalupski, M. M.Kim, E. J.Bekaii-Saab, T. S.Moore, M. J.Dawson, L. A.Ringash, J. G.Wei, A. C.